glp 1 for weight loss with insurance changes to drugs Major are coming GLP-1 loss. Here's how that could affect patients Insurance Coverage Tips for GLP-1 – GLP-1 Cost Estimator | Check

Data from 20222023 34% of GLP-1 agonist prescription fills in 2023 were for plan members without diabetes, up from 22% in 2022

Ethics declarations Ethics approval and consent to participate All procedures used for this study were approved by University of Nebraska Medical Center Institutional Animal Care and Use Committee (IACUC, approval reference number: 14-036-07-FC) and conducted according to the National Institutes of Health guiding principles for the research involving animals

Cagrilintide is further along: it has phase 3 monotherapy data, a dedicated phase 3 programme, and it is the amylin half of CagriSema, which Novo Nordisk filed with the FDA in December 2025

Diabetic retinopathy warrants particular attention, especially in patients with type 2 diabetes